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This paper discusses what is known currently about treating skin 
picking behavior in people with Prader-Willi Syndrome using 
Selective Serotonin Reuptake Inhibitors and topiramate. Because 
of small samples and flawed methodology it is argued that the 
advantages and disadvantages of either drug therapy are not fully 
known at this time, but that future research is strongly indicated. 
Some suggestions for further studies are discussed. 
The importance of establishing an effective 
treatment of the self-injurious behavior of skin 
picking in those with Prader-Willi Syndrome is 
well documented. Warnock and Kestenbaum 
(1992) reported that skin picking is frequent 
within the population and often results in 
continuous lesions that can necessitate stays in a 
hospital for treatment. Skin picking can bring 
about sepsis, acute hemorrhaging and deep 
wounds (Hellings & Warnock, 1994). Benjamin 
and Buot-Smith (1993) recorded a case of skin 
picking, of a 9-year-old boy that tore at "scabs 
through muscle down to bone and ate his flesh" 
(p. 870). Another case report reviews a woman 
with a history of hospitalization for treating 
sepsis in self-inflicted wounds who stated that 
the behavior was something that made her 
happier (Warnock & Kestenbaum, 1992). Skin 
picking is one of a variety of behaviors seen in  
Prader-Willi Syndrome that families have a hard 
time managing (Smathers, Wilson, & Nigro, 
2003). It can be seen then, that attenuating skin 
picking is not only important for the medical 
health of persons with Prader-Willi Syndrome, 
but also for their psychological health and that of 
their families. 
Prader-Willi Syndrome Defined 
Prader-Willi Syndrome (PWS) is a genetic 
disorder caused by a mutation on chromosome 
15q11-q13 by a lack of expression of the father's 
genes or by uniparental disomy in which two 
copies of the maternal chromosome are seen. It 
is manifested in an average of 1 in 10,000 births. 
The major diagnostic criteria of PWS includes: 
hypotonia and feeding complications in infancy, 
obesity, short stature, hypogonadism, mild to 
moderate mental retardation, and hyperphagia. 
43 
Beyond physical ailments, there are many 
characteristic behavioral problems associated 
with PWS. Some include: temper tantrums, 
violent outbursts, obsessive-compulsive 
behavior, stubbornness, argumentativeness, 
lying, stealing, and skin picking. 
Skin Picking 
Wigren and Heimann (2001) reported skin 
picking to be widespread within a sample of 37 
people with PWS. Parents reported that two-
thirds, or 65%, of their children with PWS 
exhibited the behavior. The action was seen 
among all ages and both sexes, showing that it is 
not limited to a specific developmental period or 
gender within the population. 
Although Wigren and Heimann's (2001) study 
is limited by its methodology, as the researchers 
did not directly observe behavior but instead 
employed parental questionnaires and follow-up 
phone calls, many important aspects of skin 
picking were documented. Data collected 
suggested that skin picking behavior begins early 
in life, with an average of 73% of the 
participants having started before the age of 
seven. The researchers saw a stable rate of 
incidence of the behavior over the life spans of 
people with PWS. This may allow for prognosis 
of life long severity of skin picking by the age of 
seven. We should be aware, however, that this 
data could be faulty because of the possibility of 
recall bias of the parents answering the 
questionnaires. 
Another important finding was that the rate of 
skin picking had a high positive correlation with 
the rate of occurrence of temper tantrums and 
overall spontaneous aggression, as well as the 
self-injurious behaviors of hair and clothes 
pulling (Wigren & Heimann, 2001). These 
findings may help caretakers and physicians to 
anticipate coping strategies as well as treatments 
for the symptom cluster. 
Research concerning the extent of skin 
picking and correlated behaviors in PWS is 
minimal. Based on these preliminary findings, 
however, it seems logical to suggest that further 
research is needed to obtain a clearer clinical  
picture of how skin picking may inform other 
behavioral issues in PWS. 
Treatment 
Selective Serotonin Reuptake Inhibitors 
(SSRIs), and topiramate have both been used in 
attempting to alleviate skin picking in persons 
with PWS. SSRIs are a class of drug often used 
in treating depression, anxiety, and personality 
disorders. Hellings and Warnock (1994) 
speculate that skin picking may be caused by a 
reduced amount of serotonin in the central 
nervous system. They explain that SSRIs 
increase the level of serotonin in the body by 
reducing its ability to be taken up from the 
synaptic cleft in neurons. Several studies (Dech 
& Budow, 1991; Hellings & Warnock, 1994; 
Warnock & Kestenbaum, 1992) that employed 
the use of SSRIs indicate that they have been 
successful in treating the symptoms of self-
injurious behavior, including hair pulling and 
skin picking, in people with Obsessive 
Compulsive Disorder. 
Topiramate has been a more recently 
investigated drug in treating skin picking. It is an 
anticonvulsant used for treating epilepsy. 
Privitera (1997) describes a number of different 
theories to explain how topiramate reduces 
seizures, but the mechanism remains uncertain. 
Through a review of the literature, Privitera 
proposes that, when at the right dosage, 
topiramate might "act through...sodium 
channels, y-aminobutyric acid (GABA), and a 
specific subtype of glutamate receptor" (p. 1165) 
by inhibiting neurons that trigger seizures. The 
forerunners of topiramate research in skin 
picking in PWS (Shapira, Lessig, Murphy, 
Driscoll, & Goodman, 2002) began testing the 
drug partly because of Privitera's (1997) 
assertion that it does not have the side effect of 
weight gain that is common in other 
anticonvulsants. This is a significant issue as 
most patients with PWS die because of 
complications of obesity (Dech & Budow, 1991). 
A survey of 369 caretakers of people with 
PWS taken in 1994 discloses that both SSRI's 
and anticonvulsants have the same rate of 
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response in treating skin picking (Stein, Keating, 
Zar, & Hollander, 1994). 
SSRI Research 
While experimenting with SSRIs was popular 
in the 1990s, relevant research has since dropped 
off with no clear conclusions as to their benefits 
in treating skin picking in PWS. In four small 
studies with one to four patients each (Benjamin 
& Buot-Smith, 1993; Hellings & Warnock, 1994; 
Warnock & Kestenbaum, 1992; Yaryura-Tobias, 
Grunes, Bayles, & Neziroglu, 1998) that 
incorporated the SSRI fluoxetine, also known as 
Prozac, and in one case study using the SSRI 
fluvoxamine (Martin et al., 1998), skin picking 
was said to improve markedly. Three of these 
studies (Benjamin & Buot-Smith, 1993; Hellings 
& Warnock, 1994; Warnock & Kestenbaum, 
1992) quantified improvement by observation of 
lesions and reported that not only did existing 
sores heal, but also no new ones were found over 
the course of treatment. However, none 
measured this in a systematic way, such as 
photographing and documenting the size of sores 
weekly, but instead relied on varied periodic 
visual checks. Systematic check-ups must be 
done carefully, however, as they could be 
detrimental to treatment because of the 
possibility that skin picking could be exacerbated 
by intensified observation (Hellings & Warnock, 
1994). 
Although Yaryura-Tobias et al.'s (1998) 
publication claims a favorable outcome in skin 
picking with the use of fluoxetine over a four-
year period, there are several reasons to question 
those findings. First, there is no mention of 
measurements gathered by the research team. 
They did monthly check-ups in a clinical setting, 
but did not report what was done during these 
evaluations. Second, many different drugs, not 
all of them SSRIs, were prescribed successively 
when others were deemed ineffective without 
any specification of a coherent rationale or 
timeline of trials being specified. Third, this 
study had only four participants. Finally, the 
institution that supported this research is 
Yaryura-Tobias' own psychological clinic in New  
York. 
It is difficult to determine whether fluoxetine 
was the cause of improvement in some cases in 
view of the fact that an array of co-therapies 
were applied in certain studies. In addition, even 
when the therapies were similar, conflicting 
results were found. Benjamin and Buot-Smith 
(1993) prescribed the opiod naltrexone along 
with fluoxetine, and it was concluded that only 
as a combination was the drug therapy 
advantageous. The same researchers 
simultaneously engaged in an unidentified 
behavioral program and rigid diet consisting of 
900 kcal a day without commenting on what 
effect either of these had on the treatment. 
Yaryura-Tobias et al. (1998) also prescribed 
naltrexone for seven months in concurrence with 
fluoxetine and thioridazine, an antipsychotic, but 
found no improvement in skin picking while 
nonetheless reporting that cognitive and 
behavioral therapies added to the original drug 
therapy's success. 
When reviewing treatment interventions of a 
single case study of an 11-year-old patient (Miss 
A), Martin et al. (1998) describe the drug 
regimen she was on during observation. This 
included the SSRI fluvoxamine, methylphenidate 
(a stimulant), valproate (an anticonvulsant and 
mood stabilizer), and lastly, growth hormone 
therapy. They state that improvement in 
"disruptive behaviors" was due to fluvoxamine, 
while valproate was meant to "target her mood 
lability" (Martin et al., 1998, p. 1268). It is not 
indicated how they came to the conclusion that 
fluvoxamine caused the reduction of the 
unwanted behaviors or what were the speculated 
effects of valproate. Because the two symptoms 
are similar in scope, it would be difficult to 
differentiate which drug affected them 
individually while Miss A was taking the 
medications simultaneously. 
In addition to skin picking, fluoxetine appears 
to positively affect many behavioral problems 
that are associated with PWS. A decrease in 
oppositional behavior was reported (Benjamin & 
Buot-Smith, 1993; Warnock & Kestenbaum, 
1992), as were lower incidences of violent 
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outbursts and hoarding (Hellings & Warnock, 
1994). Food foraging was decreased (Warnock & 
Kestenbaum, 1992) and the addition of a 
"brighter mood" was observed in one patient 
(Martin et al., 1998, p. 1268). Another patient 
was observed to have better social exchanges 
overall (Benjamin & Buot-Smith, 1993). These 
findings could be of use in improving the lives of 
people with PWS and their caretakers if 
substantiated by further study. 
Several negative side effects of SSRI use 
have also been reported in the literature. Severe 
headaches were seen in two case studies and 
were eliminated by lowering the dosage of 
fluoxetine administered (Warnock & 
Kestenbaum, 1992; Yaryura-Tobias et al., 1998). 
Martin et al. (1998) claim that people with PWS 
cannot always endure the standard dosage of 
medication given for their weight. This may 
mean that each individual patient needs to be 
carefully titrated onto an SSRI until reaching a 
safe and effective dose, or it may mean that 
people with PWS have a different universal 
standard that has not yet been found. What may 
be most problematic, though, is the claim that 
undesirable aggressive and compulsive behaviors 
seem to worsen in some cases at the beginning of 
treatment and when dosage is increased (Martin 
et al., 1998). These are important aspects of 
SSRI therapy that need to be taken into account 
when it is prescribed as well as in future research 
of the drugs. 
Weight control is of great importance when 
considering treatment of the PWS population. 
The current literature is divided as to whether 
SSRIs have the side effect of weight loss and/or 
stability in people with PWS. Martin et al. 
(1998) found that they do not aid either aspect of 
weight control. However, Benjamin and Buot-
Smith (1993) as well as Dech and Budow (1991) 
comment that the patients in their studies 
maintained and even lost a significant amount of 
weight only after treatment with fluoxetine 
began. Benjamin and Buot-Smith's (1993) 
findings are somewhat problematic, however, as 
the patient at six weeks of treatment was going 
to a gym on a regular basis for the first time in  
her life, possibly due to the reported 
improvement in mood. There is no mention of 
this fact when proclaiming weight loss due to 
flouxetine over a five and a half month period. 
Results of studies of the efficacy of SSRI 
treatment of skin picking in persons with PWS 
are mixed. Instances in which treatment was 
abandoned and then reintroduced varied widely 
in outcome. In Benjamin and Buot-Smith's 
(1993) case the doctors ceased the use of the co-
therapy naltrexone twice in order to test the 
benefit of fluoxetine alone on skin picking and 
food searching. Not only did fluoxetine fail to 
improve these symptoms, but also they seemed 
to worsen without naltrexone. The length of 
these trials may have been too short to fully 
support these findings, however. The first 
discontinuation of fluoxetine was only five days 
after its initiation, and the drug was reinstated 15 
days later. The second termination of naltrexone 
occurred after a more reasonable 34 days, but it 
was restored just ten days later. 
A different case in which unintentional 
interruption of fluoxetine intake took place had 
more positive findings with regard to SSRI 
success in treating skin picking. One of Hellings 
and Warnock's (1994) participants had to be 
taken off fluoxetine because he suffered from a 
bout of acute diarrhea. He had been taking the 
drug for over a year when this occurred, and he 
was seen to revert back to pretrial behaviors. 
Intensified skin picking along with hoarding and 
violent temper were described as "notable" (p. 
247). There is no clarification of how the doctors 
came to this conclusion, and it appears to be 
based only on qualitative observation. Also, it is 
possible that the illness itself may have caused 
these symptoms to return rather than the 
discontinuation of fluoxetine. 
Topiramate Research 
Studies of topiramate with PWS patients are 
fewer in number, but more recent. Three studies 
were found that investigated topiramate's effect 
on skin picking in a total of 15 persons with 
PWS (Shapira et al., 2002; Shapira, Lessig, 
Lewis, Goodman, & Driscoll, 2004; Smathers et 
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al., 2003). All of them suggest that topiramate 
might be useful in treating this behavior. 
Different methods were engaged in making these 
assertions. They included: weekly physical 
check-ups by investigators (Shapira et al., 2002, 
2004) and by staff at group homes in which the 
participants lived (Shapira et al., 2004), 
photographing lesions over time (Shapira et al., 
2002), and questionnaires and phone surveys 
given to parents about their children's behavior 
(Smathers et al., 2003). 
These three studies have particular 
limitations. Every study allowed participants to 
continue to take other prescription drugs while 
taking part in a topiramate trial, thus raising the 
possibility that topiramate is helpful as an 
additional treatment, but not necessarily on its 
own. Some of these accompanying drugs 
included fluoxetine and naltrexone, other 
potential treatments of skin picking in PWS. 
Also, Shapira et al.'s (2002, 2004) trial only 
lasted eight weeks, while Smathers et al. (2003) 
do not even specify what length of time they are 
reporting on, only that clinic visits were planned 
for up to "yearly thereafter" (p. 131). 
There is no consensus in the literature about 
positive side effects of topiramate on behavior. 
Smathers et al. (2003) surmise that the drug had 
an overall effect of improved mood in all of their 
participants, while Shapira et al. (2002, 2004) 
did not look at mood. 
Another favorable outcome during one trial 
was a reduction of compulsive behavior 
involving food and eating (Smathers et al., 
2003). This data is subject to parental bias 
though as reporting of this behavior was 
obtained by questionnaires and phone calls. In 
contrast, Shapira et al. (2004) acquired different 
results using the standardized Yale-Brown 
Obsessive-Compulsive Scale checklist to review 
whether compulsive behaviors were reduced 
during their topiramate trial. They found no 
statistical significant reduction in compulsive 
behaviors. We may view this finding with 
caution, however, as the Yale-Brown Obsessive-
Compulsive Scale is not a test for people with 
PWS specifically. 
There were several adverse side effects also 
described in the literature. Both Smathers et al. 
(2003) and Shapira et al. (2002, 2004) noted 
increased sleepiness in patients taking 
topiramate. To combat this, the research teams 
administered the medication at bedtime. One 
person was seen to become more irritable in the 
beginning of the trial, but after eight weeks was 
restored to baseline level with no intervention 
(Shapira et al., 2002). Two female participants in 
the same study experienced word-finding 
difficulties. One of them also felt tingling in her 
foot. However, Shapira et al.'s (2004) paper 
concludes that side effects were minimal in 
scope and that topiramate was well endured in 
general. 
The issue of topiramate's effect on weight 
control has been closely chronicled. Privitera 
(1997) found that topiramate differs from other 
anticonvulsants because of its side effect of 
weight loss. Shapira et al. (2002, 2004) cite this 
as part of the rationale for experimenting with it 
in patients with PWS. Two of the three 
participants in Shapira et al.'s (2002) study either 
did not gain weight or lost some, while the third 
gained four and a half pounds over the eight 
week trial. These varied results support the need 
for further research. A year later, Smathers et al. 
(2003) reported that all seven participants in 
their inquiry benefited in regards to weight while 
on topiramate; not a single case of weight gain 
took place. This contradicted Shapira et al.'s 
(2004) study of nine participants, which found 
no evidence of weight loss or increased weight 
stability when comparing BMI at baseline and 
eight weeks. 
Later research suggests topiramate may have 
a weight loss mechanism, but that it is not 
triggered in people with PWS. In a study of 61 
obese patients with binge-eating disorder (BED), 
there was a statistically significant loss of body 
mass over the 14-week trial as well as fewer 
weekly bingeing episodes (McElroy et al., 2004). 
The power of this study is heightened by the fact 
that it was randomized, double blind and placebo 
controlled, but it also had a high early 
termination rate as 26 participants dropped out. 
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Because BED has similar symptoms to PWS, 
such as obesity and compulsive eating, research 
in the use of topiramate in both disorders may 
shine light on how these symptoms are 
manifested in the biology of both of these 
groups. 
In an attempt to pinpoint the origin of 
uncontrollable hunger in people with PWS in 
relation to topiramate, Shapira et al. (2005) used 
functional magnetic resonance imaging, better 
known asfMRI. They did one scan pre-treatment 
with topiramate and one post-treatment on three 
different adults with PWS who did not respond 
to the drug in regard to weight loss. When 
compared with other obese patients with no 
PWS, they found that the hypothalamus, where 
satiety is recognized, operates slower in those 
with PWS, with a difference of 11 minutes. 
When compared to normal weight people the 
disparity is even larger, at 14 minutes. This study 
may indicate an abnormality within the central 
nervous system that affects the ability of food 
intake to induce satiety in people with PWS. It 
could also lead to an abandonment of topiramate 
as a weight loss treatment for PWS patients, as 
no difference in satiety was found pre and post 
treatment in the hypothalamus. More research is 
indicated though, as a small sample was used 
and all participants were taking other 
medications at the time of the study. 
Even if it does not help with weight control, 
topiramate's efficacy in treating skin picking 
behavior is well worth pursuing, as there is 
evidence of its success. Shapira et al.'s (2002) 
case report of three individuals states that each 
participant claimed that the desire to pick 
decreased while on the drug. All of them 
continued to take topiramate after the eight-week 
trial ended and maintained improvement of self-
injurious behavior. These same participants 
performed better on the Gordon Diagnostic 
System's Delay Task while on topiramate. This 
ranks the ability to repress and postpone 
impetuous behavior, which is associated with 
skin picking. Also, in 2004, Shapira et al. tell of 
one participant's experience after ending eight 
months of topiramate treatment. After taking  
lower amounts of the drug over time, a 
resurgence of skin picking behavior occurred. 
Other concrete observations that support the 
beneficial effects of topiramate are decreases in 
the count and measurement of lesions (Shapira et 
al., 2002, 2004). In the only study to utilize 
statistics, data were evaluated with the t test 
(Shapira et al., 2004). A significant reduction 
with treatment was found at the .01 level on the 
Self-Injury and Self-Restraint Checklist when 
comparing baseline and eight weeks of 
treatment. 
Flaws in Research 
All of the studies described here that directly 
addressed PWS use the method of open-label 
observation. It is possible that the effects of 
observer bias affected the experimenters and 
parents. These can include, but are not limited to, 
difficulty in obtaining objective observations and 
the skewing of results due to expectations. These 
studies are further restricted by the fact that 
observation can only describe the chosen 
behavior, but never account for the cause of it. 
Another variable that may have altered the 
results of these studies is the placebo effect. In 
other words, it is possible that the patients 
themselves altered their behaviors as a result of 
their own perception or anticipation of the 
results. 
Research of SSRI and topiramate use in 
addressing self-injurious behavior in PWS has 
been limited to a small number of patients and 
done by a sparse number of researchers. This is 
probably because it is a rare disorder. A search of 
the literature revealed only twelve case studies 
on SSRI use in PWS. Two of them do not focus 
on skin picking, but instead on hair pulling, 
hoarding and violent temper (Dech & Budow, 
1991; Hellings & Warnock, 1994). Interestingly, 
Warnock is listed as the author in two of the 
journal articles (Hellings & Warnock, 1994; 
Warnock & Kestenbaum, 1992) and two patients 
seem to be the same people in both articles. So, 
by that count, there may only be eight case 
studies that target SSRI use in treating skin 
picking in PWS. No judgment about the 
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treatment can be made based on such a low 
number of cases, as the samples may not be 
representative of the entire PWS population. 
Even though topiramate research includes a 
higher number of participants (15), it is also 
impossible to consider this a representative 
sample. This number counts the three 
participants in both Shapira et al.'s 2002 and 
2004 studies only once. 
Allowing participants to remain on 
concomitant drug therapies is detrimental to 
findings, as there is no way to ensure that the 
trial drug alone was effective. Most of the 
studies discussed involved patients who were 
taking more medications than the drug on trial. 
There was no universal standard for 
measuring either sores or the behavior of skin 
picking itself, although Shapira et al. (2002) 
photographed patients in their case studies of 
three patients. Even then, they did not begin the 
documentation in one case until after topiramate 
use had begun. Smathers et al. (2003) relied on 
parental reporting which in itself is problematic, 
as expectations as well as desired change of 
behavior may have affected the data. While 
weekly check-ups by doctors and researchers is 
important, only one case was said to look at the 
patient fully naked as she had been noted to hide 
the behavior (Shapira et al., 2002). It is difficult 
to substantiate the results of these studies 
without the means of definitive measurements of 
skin picking and lesion size. 
Conclusion 
Although both SSRIs and topiramate appear 
to be promising treatments for skin picking in 
PWS, it is impossible to ascertain whether they 
are effective drug therapies at this time. There is 
not enough published evidence devoid of 
methodological problems to comprehensively 
support the efficacy of either one. However, all 
studies reviewed for this investigation do 
indicate that more research is needed as both 
SSRIs and topiramate demonstrated that in some 
instances they seem to alleviate skin picking 
behavior. 
Suggestions for Further Research 
Wigren and Heimann's (2001) survey found 
that 70% of participants that actively engaged in 
skin picking behavior did so when alone. Sixty-
one percent of those parents informed the 
researchers that they believed their children not 
only performed the behavior secretly but also 
attempted to conceal any resultant injury. These 
findings emphasize a need for orderly methods in 
documenting how often participants skin pick so 
that the rate of the behavior can be accurately 
measured. This could be done by observing 
participants behind a two-way mirror for a 
certain amount of time per day while tallying 
how often they exhibit skin picking behavior 
over the course of the study. Also, photographing 
existing sores at baseline and any newly 
developed sores during treatment would ensure 
proper verification of results. In order to thwart 
issues of concealed lesions, periodic full body 
exams could be part of the methodology. The 
possibility of reinforcing the behavior of skin 
picking with these exams (Hellings & Warnock, 
1994) would have to be taken into consideration 
and controlled. 
The largest total number of participants in any 
of the studies concerning drug therapy and skin 
picking mentioned was eight (Shapira et al., 
2004). Clearly, more participants are needed to 
validate the accuracy of population 
representation. This could prove difficult, as 
PWS itself is a rare disorder. A further 
complication may be that recruiting children and 
mentally retarded adults with PWS would 
require obtaining informed consent from 
guardians. 
Some of these studies recruited people 
through group homes that specialized in PWS 
care (Shapira et al., 2002, 2004), through referral 
or in-patient hospital care (Benjamin & Buot-
Smith, 1993; Dech & Budow, 1991; Hellings & 
Warnock, 1994; Warnock & Kestenbaum, 1992; 
Yaryura-Tobias et al., 1998) or through the use of 
PWS non-profit group lists (Stein et al., 1994; 
Wigren & Heimann, 2001). It may prove difficult 
to recruit participants without these methods, but 
to avoid sample bias a more random procedure 
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must be used in enrolling and assigning them. 
Future research of SSRI and topiramate 
treatment of skin picking would benefit by 
arranging trials of appropriate time lines. Shapira 
et al.'s (2002, 2004) research only tested 
topiramate for an eight-week period. Longer 
trials would help authenticate findings. Of 
course, a review of known data concerning the 
safety of a particular drug would have to be 
taken into consideration when planning the 
duration of experiments. 
Regardless of specific experimental design, 
studies that investigate the efficacy of these 
drugs should be double-blind and placebo-
controlled. This would safeguard against the bias 
associated with researchers and participants. It 
may also be useful to directly compare SSRIs 
and topiramate in one study. Ethical issues may 
arise regarding the use of placebo in a population 
that is characterized as being mild to moderately 
mentally retarded, however. Guidelines for this 
type of situation would have to be reviewed by 
researchers and the Institutional Review Board in 
charge of approving the research. 
A further control needed to increase the 
potency of subsequent investigation of SSRI's 
and topiramate is testing them as monotherapies. 
It would be ideal if none of the participants were 
taking other prescription drugs. Also, if any 
behavioral therapies were to be used, they would 
need to be used on all participants uniformly. 
In order to clearly assess behavioral problems 
other than skin picking, standardized tests may 
be of use. Shapira et al. (2004) had much success 
with this in recording compulsivity. Care should 
be taken when deciding which to use with regard 
to the attributes of PWS, such as IQ of 
participants. It may even be advantageous to 
formulate new tests designed solely to measure 
particular behaviors in people with PWS. 
Finally, empirical research must eventually be 
based on more than individual case reviews, and 
must ultimately rely on statistically significant 
findings. If a large enough sample can be found 
and valid, reliable data collected, the appropriate 
statistical test can be found depending on the 
design of the experiment. 
PWS presents symptoms that adversely affect 
patients and their families. These preliminary 
findings that SSRIs and topiramate may alleviate 
skin picking and other self-injurious behaviors 
necessitates that these drugs be more extensively 
tested in larger, better-controlled studies. 
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